Manuel Pérez-Encinas

16PUBLICATIONS
85CO-AUTHORS
Haematological tumoursMedical mycologyMolecular targetsCardiology (incl. cardiovascular diseases)Respiratory diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Aug 04, 2026
Survival outcomes and treatment patterns in myelofibrosis in the JAK inhibitor era.

|Apr 17, 2025
Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study.

Lucía Pérez-Lamas, Adrián Segura Diaz, Regina García Delgado

|Aug 30, 2024
Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis.

Irene Pastor-Galán, Arturo Pereira, Eduardo Arellano-Rodrigo

|Jul 14, 2023
Presence of Myeloid Mutations in Patients with Chronic Myeloid Leukemia Increases Risk of Cardiovascular Event on Tyrosine Kinase Inhibitor Treatment.

Ruth Stuckey, Adrián Segura-Díaz, María Nieves Sáez Perdomo

|Feb 25, 2023
Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors.

Lucía Pérez-Lamas, Alejandro Luna, Concepción Boque

|Nov 14, 2022
CNL and aCML should be considered as a single entity based on molecular profiles and outcomes.

Gonzalo Carreño-Tarragona, Alberto Álvarez-Larrán, Claire Harrison

Pageof 3

Frequent Collaborators

5 joint publications

David Martínez-Cuadrón

5 joint publications

Miguel-Ángel Sanz

5 joint publications

Juan-Carlos Hernández-Boluda

4 joint publications

Valentín Garcia-Gutiérrez